Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
Open Access
- 13 July 2021
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (7) , 1-11
Abstract
Hypoxia, a characteristic of most human solid tumors, is a major obstacle to successful radiotherapy. While moderate acute hypoxia increases cell survival, chronic cycling hypoxia triggers adaptation processes, leading to the clonal selection of hypoxia-tolerant, apoptosis-resistant cancer cells. Our results demonstrate that exposure to acute and adaptation to chronic cycling hypoxia alters the balance of Bcl-2 family proteins in favor of anti-apoptotic family members, thereby elevating the apoptotic threshold and attenuating the success of radiotherapy. Of note, inhibition of Bcl-2 and Bcl-xL by BH3-mimetic ABT-263 enhanced the sensitivity of HCT116 colon cancer and NCI-H460 lung cancer cells to the cytotoxic action of ionizing radiation. Importantly, we observed this effect not only in normoxia, but also in severe hypoxia to a similar or even higher extent. ABT-263 furthermore enhanced the response of xenograft tumors of control and hypoxia-selected NCI-H460 cells to radiotherapy, thereby confirming the beneficial effect of combined treatment in vivo. Targeting the Bcl-2 rheostat with ABT-263, therefore, is a particularly promising approach to overcome radioresistance of cancer cells exposed to acute or chronic hypoxia with intermittent reoxygenation. Moreover, we found intrinsic as well as ABT-263- and irradiation-induced regulation of Bcl-2 family members to determine therapy sensitivity. In this context, we identified Mcl-1 as a resistance factor that interfered with apoptosis induction by ABT-263, ionizing radiation, and combinatorial treatment. Collectively, our findings provide novel insights into the molecular determinants of hypoxia-mediated resistance to apoptosis and radiotherapy and a rationale for future therapies of hypoxic and hypoxia-selected tumor cell fractions.Keywords
Funding Information
- Deutsche Krebshilfe (70112711, 110344, 70112711)
This publication has 49 references indexed in Scilit:
- Past, present, and future of radiotherapy for the benefit of patientsNature Reviews Clinical Oncology, 2012
- Imaging hypoxia to improve radiotherapy outcomeNature Reviews Clinical Oncology, 2012
- Hypoxia-Induced Modulation of Apoptosis and BCL-2 Family Proteins in Different Cancer Cell TypesPLOS ONE, 2012
- The Novel Bcl-2 Inhibitor ABT-737 Is More Effective in Hypoxia and Is Able to Reverse Hypoxia-Induced Drug Resistance in Neuroblastoma CellsMolecular Cancer Therapeutics, 2011
- The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapyCell Death & Differentiation, 2011
- Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1Journal of Clinical Investigation, 2011
- Hypoxia Suppression of Bim and Bmf Blocks Anoikis and Luminal Clearing during Mammary MorphogenesisMolecular Biology of the Cell, 2010
- BCL-xL Is a Target Gene Regulated by Hypoxia-inducible Factor-1αJournal of Biological Chemistry, 2009
- Expression of p53 protein and the apoptotic regulatory molecules Bcl-2, Bcl-XL, and Bax in locally advanced squamous cell carcinoma of the lungLung Cancer, 2004
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002